SI3191120T1 - Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom - Google Patents

Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom

Info

Publication number
SI3191120T1
SI3191120T1 SI201532020T SI201532020T SI3191120T1 SI 3191120 T1 SI3191120 T1 SI 3191120T1 SI 201532020 T SI201532020 T SI 201532020T SI 201532020 T SI201532020 T SI 201532020T SI 3191120 T1 SI3191120 T1 SI 3191120T1
Authority
SI
Slovenia
Prior art keywords
antagonists
progression
inhibit
psoriatic arthritis
structural damage
Prior art date
Application number
SI201532020T
Other languages
English (en)
Slovenian (sl)
Inventor
Shephard Mpofu
Hanno Richards
Gregory Ligozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3191120(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI3191120T1 publication Critical patent/SI3191120T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
SI201532020T 2014-09-10 2015-09-08 Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom SI3191120T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
EP15767597.6A EP3191120B1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
SI3191120T1 true SI3191120T1 (sl) 2024-10-30

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201532020T SI3191120T1 (sl) 2014-09-10 2015-09-08 Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom

Country Status (22)

Country Link
US (2) US11278618B2 (enExample)
EP (2) EP3191120B1 (enExample)
JP (4) JP2017528465A (enExample)
KR (2) KR20170045240A (enExample)
CN (4) CN115944734A (enExample)
AU (2) AU2015313827C1 (enExample)
BR (1) BR112017003332A2 (enExample)
CA (1) CA2960754A1 (enExample)
DK (1) DK3191120T3 (enExample)
ES (1) ES2981697T3 (enExample)
FI (1) FI3191120T3 (enExample)
HR (1) HRP20240921T1 (enExample)
HU (1) HUE067081T2 (enExample)
LT (1) LT3191120T (enExample)
MX (1) MX2017003216A (enExample)
PL (1) PL3191120T3 (enExample)
PT (1) PT3191120T (enExample)
RS (1) RS65851B1 (enExample)
RU (1) RU2697383C2 (enExample)
SI (1) SI3191120T1 (enExample)
SM (1) SMT202400285T1 (enExample)
WO (1) WO2016038538A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2960754A1 (en) 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
JP6931648B2 (ja) 2015-10-27 2021-09-08 ユーシービー バイオファルマ エスアールエル 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
US10676522B2 (en) * 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
CA3073597A1 (en) * 2017-08-23 2019-02-28 Eli Lilly And Company Treatment of genital psoriasis
CN111344043A (zh) * 2017-11-02 2020-06-26 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法
MA56124A (fr) * 2019-06-04 2022-04-13 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
KR102576258B1 (ko) 2019-12-05 2023-09-11 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2171449A2 (en) 2007-06-20 2010-04-07 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
WO2010034443A1 (en) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof
EP2625199B1 (en) * 2010-10-08 2017-11-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
HRP20251174T1 (hr) * 2010-11-05 2025-11-21 Novartis Ag Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
EP2783014A1 (en) * 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
CA2960754A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Also Published As

Publication number Publication date
JP2025024104A (ja) 2025-02-19
JP2023109973A (ja) 2023-08-08
CN115944734A (zh) 2023-04-11
AU2018201410A1 (en) 2018-03-22
JP7288927B2 (ja) 2023-06-08
RU2697383C2 (ru) 2019-08-13
KR20230170796A (ko) 2023-12-19
RU2017107501A3 (enExample) 2019-03-12
RU2017107501A (ru) 2018-10-10
RS65851B1 (sr) 2024-09-30
CN115957326A (zh) 2023-04-14
JP2017528465A (ja) 2017-09-28
HUE067081T2 (hu) 2024-09-28
MX2017003216A (es) 2017-05-23
LT3191120T (lt) 2024-07-25
JP7591092B2 (ja) 2024-11-27
US20170281762A1 (en) 2017-10-05
AU2015313827C1 (en) 2018-08-30
EP4406969A2 (en) 2024-07-31
CN107073110A (zh) 2017-08-18
SMT202400285T1 (it) 2024-09-16
US20220313818A1 (en) 2022-10-06
PL3191120T3 (pl) 2024-08-26
HRP20240921T1 (hr) 2024-10-11
US11278618B2 (en) 2022-03-22
PT3191120T (pt) 2024-07-16
AU2015313827B2 (en) 2018-02-15
DK3191120T3 (da) 2024-07-15
JP2021152021A (ja) 2021-09-30
BR112017003332A2 (pt) 2017-11-28
ES2981697T3 (es) 2024-10-10
CN113069542A (zh) 2021-07-06
KR20170045240A (ko) 2017-04-26
FI3191120T3 (fi) 2024-07-10
AU2015313827A1 (en) 2017-02-16
CA2960754A1 (en) 2016-03-17
EP3191120B1 (en) 2024-04-10
EP4406969A3 (en) 2024-11-27
WO2016038538A1 (en) 2016-03-17
EP3191120A1 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
LT3191120T (lt) Il-17 antagonistų panaudojimas struktūrinio pažeidimo progresavimui slopinti, sergant psoriaziniu artritu
GB201416102D0 (en) Impovements In or Relating To Shower Rods
IL251904B (en) Epilimod for use in the treatment of melanoma
GB201702982D0 (en) Improvements in or relating to centralisers
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL237705B (en) Placement of electrodes near the heart
PL3137622T3 (pl) Sposoby redukowania spadku pojemności życiowej
GB201705271D0 (en) Technology to facilitate and promote the use of environmentally-friendly transport
ZA201702488B (en) Improvements in or relating to connecting devices
PL2965765T3 (pl) Zastosowanie adelmidrolu w leczeniu dysfunkcji nabłonka
GB201416463D0 (en) Improvements in or relating to temporary structures
GB2545716B (en) Improvements in or relating to the separation of radon
GB201419593D0 (en) Improvements in or relating to connecting devices
UA28633S (uk) Кутова оздоба до пам'ятника намогильного
ZA201408464B (en) Composition for the use in treatment of asthma
GB201415704D0 (en) Improvements in or Relating to Storage
GB201415702D0 (en) Improvements in or relating to storage
GB201415705D0 (en) Improvements in or Relating to Storage
GB201404391D0 (en) Novel compositions having use in therapy
GB201406072D0 (en) Improvements in or relating to storage
GB201406078D0 (en) Improvements in or relating to storage
GB201412345D0 (en) Improvements in and relating to devices